<DOC>
	<DOCNO>NCT02514850</DOCNO>
	<brief_summary>This single centre , randomise , double-blind , double-dummy , 3-treatment , 3-period cross-over , euglycaemic clamp study subject type 2 diabetes stable insulin treatment . Each subject randomly allocate treatment sequence administer single subcutaneous dos 0.8 U/kg Biochaperone® Combo , 0.8 U/kg Humalog® Mix25 simultaneous subcutaneous injection 0.2 U/kg Humalog® 0.6 U/kg Lantus® three separate dose visit .</brief_summary>
	<brief_title>A Trial Compare Pharmacodynamic Pharmacokinetic Properties Biochaperone® Combo With Humalog® Mix25 With Simultaneous Injections Humalog® Lantus® Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<criteria>Type 2 diabetes mellitus ( diagnose clinically ) ≥ 12 month HbA1c level ≤ 9.0 % Total insulin dose &lt; 1.2 U/kg/day Body mass index 20.0 35.0 kg/m2 ( inclusive ) Body weight ≤ 125.0 kg Fasting serum Cpeptide ≤ 1 nmol/L Treated stable insulin regimen ≥ 3 month prior screen Type 1 diabetes mellitus Known suspect allergy trial product relate product Previous participation trial . Participation define randomised Participation clinical trial within 3 month prior trial Clinically significant abnormal haematology , biochemistry , lipid , urinalysis screening test , judge Investigator consider underlying disease Supine blood pressure screen outside range 90160 mmHg systolic 5095 mmHg diastolic and/or rest supine heart rate outside range 50 90 beat per minute . This exclusion criterion also pertain subject antihypertensive Use GLP1 receptor agonists oral antidiabetic drug ( OADs ) stable intake metformin within 4 week prior screen Women child bear potential , willing use contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>